Ignite Creation Date:
2025-12-26 @ 11:07 AM
Ignite Modification Date:
2026-02-25 @ 9:48 PM
Study NCT ID:
NCT02332512
Status:
UNKNOWN
Last Update Posted:
2017-02-24
First Post:
2015-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
HR-APTN-Ⅲ-NSCLC-02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None